Vaborbactam

File:Vaborbactam.svg

Vaborbactam.svg

Vaborbactam is a beta-lactamase inhibitor used in combination with the antibiotic meropenem to treat certain serious bacterial infections. It is particularly effective against carbapenem-resistant Enterobacteriaceae (CRE), which are a significant cause of hospital-acquired infections.

Mechanism of Action

Vaborbactam works by inhibiting the activity of beta-lactamase enzymes produced by bacteria. These enzymes typically break down beta-lactam antibiotics, rendering them ineffective. By inhibiting these enzymes, vaborbactam allows meropenem to retain its antibacterial activity against resistant strains.

Clinical Use

Vaborbactam is used in combination with meropenem for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, and for the treatment of complicated intra-abdominal infections (cIAIs). It is also used for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia.

Pharmacokinetics

Vaborbactam is administered intravenously and has a half-life that allows for dosing every 8 hours when combined with meropenem. It is primarily excreted unchanged in the urine.

Side Effects

Common side effects of vaborbactam include headache, nausea, diarrhea, and infusion site reactions. Serious side effects may include allergic reactions and seizures.

Approval and Availability

Vaborbactam was approved by the Food and Drug Administration (FDA) in 2017 for use in combination with meropenem. It is marketed under the brand name Vabomere.

See Also

• Beta-lactamase inhibitor
• Meropenem
• Carbapenem-resistant Enterobacteriaceae
• Hospital-acquired infection
• Urinary tract infection
• Intra-abdominal infection
• Pneumonia

External Links

Vaborbactam
INN
Drug class
Routes of administration	Intravenous
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG